Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 13/10/2023
• Auteurs : Thiébaud PicartJohan PalludJulien BerthillerChloé DumotMoncef BerhoumaFrançois DucrayXavier ArmoiryJennifer MargierPascale GuerrePascale VarletDavid MeyronetPhilippe MetellusJacques GuyotatElsa MagroPhilippe MeneiHugues LoiseauHenri DufourNicolas ReynsMichel LonjonEdouard GimbertEvelyne EmeryWalid FarahFrançois VassalPierre Jean Le ResteIlyes ZemmouraLuc BauchetOlivier LangloisFabrice ParkerEmmanuel MandonnetFaillot ThierryRémy GuillevinLuc TaillandierAnne TermozNathalie PerretonEstelle Bravant
• Organismes : Hospices Civils de Lyon
• Publié dans Journal of Neurosurgery le 26/10/2020

---

Résumé : OBJECTIVE Only one phase III prospective randomized study, published in 2006, has assessed the performance of 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery (FGS) for glioblastoma resection. The aim of the RESECT study was to compare the onco-functional results associated with 5-ALA fluorescence and with white-light conventional microsurgery in patients with glioblastoma managed according to the current standards of care. METHODS This was a phase III prospective randomized single-blinded study, involving 21 French neurosurgical centers, comparing 5-ALA FGS with white-light conventional microsurgery in patients with glioblastoma managed according to the current standards of care, including neuronavigation use and postoperative radiochemotherapy. Randomization was performed in a 1:1 ratio stratified by institution. 5-ALA (20 mg/kg) or placebo (ascorbic acid) was administered orally 3-5 hours before the incision. The primary endpoint was the rate of gross-total resection (GTR) blindly assessed by an independent committee. Patients without a confirmed pathological diagnosis of glioblastoma or with unavailable postoperative MRI studies were excluded from the per-protocol analysis. RESULTS Between March 2013 and August 2016, a total of 171 patients were assigned to the 5-ALA fluorescence group (n = 88) or to the placebo group (n = 83). Twenty-four cases were excluded because the WHO histological criteria of grade 4 glioma were not met. The proportion of GTR was significantly higher in the 5-ALA fluorescence group (53/67, 79.1%) than in the placebo group (33/69, 47.8%; p = 0.0002). After adjustment for age, preoperative Karnofsky Performance Scale score, and tumor location, GTR was still associated with 5-ALA fluorescence (OR 4.13 [95% CI 1.94-8.79]). The mean 7-day postoperative Karnofsky Performance Scale score (≥ 80% in 49/71, 69.0% [5-ALA group]; 50/71, 70.4% [placebo group], p = 0.86) and the proportion of patients with a worsened neurological status 3 months postoperatively (9/68, 13.2% [5-ALA group]; 9/70, 12.9% [placebo group], p = 0.95) were similar between groups. Adverse events related to 5-ALA intake were rare and consisted of photosensitization in 4/87 (4.6%) patients and hepatic cytolysis in 1/87 (1.1%) patients. The 6-month PFS (70.2% [95% CI 57.7%-79.6%] and 68.4% [95% CI 55.7%-78.1%]; p = 0.39) and 24-month OS (30.1% [95% CI 18.9%-42.0%] and 37.7% [95% CI 25.8%-49.5%]; p = 0.89) did not significantly differ. In multivariate analysis, GTR was an independent predictor of PFS (hazard ratio 0.56 [95% CI 0.36-0.86], p =

---

Source

---

• Type de publi. :
• Date de publi. : 13/10/2023
• Auteurs : Philippe PierratPierre MagriJean-Jacques Gaumet
• Organismes : Laboratoire Lorrain de Chimie Moléculaire Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 12/10/2023
• Auteurs : Daniela Rodrigues-BrazLinxin ZhuEmmanuelle GélizéJean-Pierre ClarinXavier ChatagnonYoucef BenzinePhilippe RampignonAgathe ThouveninJean-Louis BourgesFrancine Behar-CohenMin Zhao
• Organismes : Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Unité de Technologies Chimiques et Biologiques pour la Santé Agence Générale des Equipements et Produits de Santé [Paris] Centre de Recherche des Cordeliers Hôpital Cochin [AP-HP] Centre de Recherche des Cordeliers Hôpital Cochin [AP-HP] Hôpital Foch [Suresnes] Centre de Recherche des Cordeliers
• Publié dans Pharmaceuticals le 26/10/2020

---

Résumé : Abnormal corneal wound healing can compromise corneal transparency and lead to visual impairment. Mineralocorticoid receptor antagonists (MRA) are promising candidates to promote corneal remodeling with anti-inflammatory properties and lack gluococorticoids-associated side effects. In this preclinical study, a new polymer-free hydroxypropyl-gamma-cyclodextrin-based eyedrop containing 0.1% spironolactone (SPL), a potent but non-water-soluble MRA, was investigated for its ocular surface tolerance and efficacy in a rat model of corneal wound healing. SPL eyedrops were stable for up to 9 months at 4 °C. The formulation was well-tolerated since no morphological changes or inflammatory reactions were observed in the rat cornea after multiple daily instillations over 7 days. SPL eyedrops accelerated rat corneal wound healing, reduced corneal edema and inflammation, enhanced epithelial integrity, and improved nerve regeneration, suggesting restoration of corneal homeostasis, while potassium canrenoate, an active and soluble metabolite of SPL, had no effect. SPL eyedrops could benefit patients with impaired corneal wound healing, including that secondary to glucocorticoid therapy. Repurposing known drugs with known excipients will expedite translation to the clinic.

---

Source

---

• Type de publi. :
• Date de publi. : 12/10/2023
• Auteurs : Philippe PierratPierre MagriJean-Jacques Gaumet
• Organismes : Laboratoire Lorrain de Chimie Moléculaire Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 11/10/2023
• Auteurs : Mikael CohenFabien RollotMarc DebouverieHélène ZéphirSandra VukusicJérôme de SèzePierre M. LabaugeAurélie RuetÉric BergerDavid-Axel LaplaudJ CironBertrand BourreEmmanuelle Le PageCaroline PapeixEric ThouvenotAbdullatif Al KhedrBruno StankoffJean PelletierÉlisabeth MaillartOlivier CasezThibault MoreauGilles DeferPierre ClavelouPhilippe CabreSolène MoulinJean-Philippe NeauAbir WahabKarolina HankiewiczInès DoghriHaifa KhaledCorinne PottierLaurent MagyDalia Meshaka-Dimitri-BoulosDimitri BoulosOlivier HeinzlefJean-Philippe CamdessanchéMarc CoustansChantal NifleDavid BrassatRomain CaseyChristine Lebrun-Frenay
• Organismes : Centre Hospitalier Universitaire de Nice Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Universitaire de Nancy Centre Hospitalier Régional Universitaire [CHU Lille] Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Toulouse Institut Toulousain des Maladies Infectieuses et Inflammatoires CHU Rouen Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] CHU Amiens-Picardie Aix Marseille Université Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU Henri Mondor [Créteil] Centre Hospitalier Régional Universitaire de Tours CHU Limoges Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Universitaire de Nice

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/10/2023
• Auteurs : Elise DreanoPierre-Régis BurgelAurélie HattonNaim BouazzaBenoit ChevalierJulie MaceySylvie LeroyIsabelle DurieuLaurence WeissDominique GrenetNathalie StremlerCamille OhlmannPhilippe ReixMichele PorzioPauline Roux ClaudeNatacha RémusBenoit DouvrySylvie MontcouquiolLaure CossonJulie MankikianJeanne LanguepinVeronique HoudouinLaurence Le ClaincheAnne GuillaumotDelphine PouradierAdrien TissotPascaline PriouLaurent MélyFrederique ChedevergneMuriel LebourgeoisJean LebihanClémence MartinFlora ZavalaJennifer da SilvaLydie LemonnierMairead Kelly-AubertAnita GolecPierre FoucaudChristophe MarguetAleksander EdelmanAlexandre HinzpeterPaola de CarliEmmanuelle GirodonIsabelle Sermet-GaudelusIwona Pranke
• Organismes : Institut Necker Enfants-Malades Institut Cochin Institut Necker Enfants-Malades Institut Necker Enfants-Malades Hospices Civils de Lyon Institut Necker Enfants-Malades Institut Necker Enfants-Malades Institut Necker Enfants-Malades Institut Necker Enfants-Malades Institut Necker Enfants-Malades Institut Necker Enfants-Malades Institut Necker Enfants-Malades Institut Necker Enfants-Malades
• Publié dans European Respiratory Journal le 23/10/2020

---

Résumé : Background Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry the F508del allele on the CF transmembrane conductance regulator ( CFTR ) gene. Considering that pwCF carrying rare variants may benefit from ETI, including variants already validated by the US Food and Drug Administration (FDA), a compassionate use programme was launched in France. PwCF were invited to undergo a nasal brushing to investigate whether the pharmacological rescue of CFTR activity by ETI in human nasal epithelial cell (HNEC) cultures was predictive of the clinical response. Methods CFTR activity correction was studied by short-circuit current in HNEC cultures at basal state (dimethyl sulfoxide (DMSO)) and after ETI incubation and expressed as percentage of normal (wild-type (WT)) CFTR activity after sequential addition of forskolin and Inh-172 (Δ I ETI/DMSO %WT). Results 11 pwCF carried variants eligible for ETI according to the FDA label and 28 carried variants not listed by the FDA. ETI significantly increased CFTR activity of FDA-approved CFTR variants (I601F, G85E, S492F, M1101K, R347P, R74W;V201M;D1270N and H1085R). We point out ETI correction of non-FDA-approved variants, including N1303K, R334W, R1066C, Q552P and terminal splicing variants (4374+1G>A and 4096-3C>G). Δ I ETI/DMSO %WT was significantly correlated to change in percentage predicted forced expiratory volume in 1 s and sweat chloride concentration (p<0.0001 for both). G85E, R74W;V201M;D1270N, Q552P and M1101K were rescued more efficiently by other CFTR modulator combinations than ETI. Conclusions Primary nasal epithelial cells hold promise for expanding the prescription of CFTR modulators in pwCF carrying rare mutants. Additional variants should be discussed for ETI indication.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 11/10/2023
• Auteurs : Naïl BenallegueFabien RollotS WiertlewskiRomain CaseyMarc DebouverieEmmanuelle Le PageJérôme de SèzeJonathan CironAurélie RuetPierre M. LabaugeÉlisabeth MaillartThi Helene ZephirCaroline PapeixGilles-Louis DeferChristine Lebrun-FrenayThibault MoreauEric BergerBruno StankoffPierre ClavelouOlivier HeinzlefJean PelletierEric ThouvenotAbdullatif Al KhedrBertrand BourreOlivier CasezPhilippe CabreAbir WahabLaurent MagyJean-Philippe CamdessanchéInès DoghriSolène MoulinHaifa KhaledKarolina HankiewiczJean-Philippe NeauCéline LabeyrieDalia Dimitri BoulosSandra VukusicDavid-Axel Laplaud
• Organismes : Centre Hospitalier Universitaire d'Angers Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Service de neurologie [CHRU Nancy] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] CIC Strasbourg Service de Neurologie [Strasbourg] Institut Toulousain des Maladies Infectieuses et Inflammatoires Département Neurologie [CHU Toulouse] Centre d'investigation clinique de Toulouse Centre Hospitalier Universitaire de Bordeaux Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] CHU Pitié-Salpêtrière [AP-HP] Hôpital Roger Salengro [Lille] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Service de Neurologie [CHU Caen] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Caen] Service de Neurologie [CHU Nice] Unité de Recherche Clinique Côte d’Azur Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Service de Neurologie [CHRU Besançon] CHU Saint-Antoine [AP-HP] Service Neurologie [CHU Clermont-Ferrand] Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] Institut de Génomique Fonctionnelle Service de Neurologie [CHU Nimes] Service de neurologie [Amiens] CHU Rouen CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Hôpital Henri Mondor Service de Neurologie [CHU Limoges] Service de Neurologie [CHU de Saint-Étienne] Centre Hospitalier Régional Universitaire de Tours Service de neurologie [Reims] Centre Hospitalier Sud Francilien - Centre Hospitalier d'Evry Centre Hospitalier de Saint-Denis [Ile-de-France] Service de neurologie [CHU de Poitiers] Service de neurologie [Le Kremlin Bicêtre] Service de neurologie [Le Kremlin Bicêtre] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital

---

Résumé : Introduction: Moderately-effective therapies (MET) have been the main treatment in pediatric- onset multiple sclerosis (POMS) for years. Despite the expanding use of highly-effective therapies (HET), therapeutic guidelines for POMS are missing. Objectives/Aims: To assess the real-world effectiveness of HET as immediate treatment compared with MET on disease activity. Methods: In this retrospective observational study, we used datafrom 36 French MS expert centers participating in the Observatoire Français de la Sclérose en plaques (OFSEP), the French MS registry. We included treatment-naïve children (aged under 18 years) with relapsing-remitting MS who initiated HET or MET from 2010 to 2022. We used an innovative statistical method to model the logarithm of event rates by a penalized splines of time, allowing the possibility to model the effects of covariates in a flexible way considering non-linearity and interactions. Results: A total of 530 children were identified and met inclusion criteria (422 MET and 108 HET). Both HET and MET treatment strategies reduced the risk of first relapse within the first 2 years. HET dampened the occurrence of a first relapse with a 54% risk reduction compared to MET (adjusted Hazard Ratio HR 0.46 [95% CI 0.31-0.67]; p<0.001) and a sustained effect over 5 years of follow-up, confirmed on MRI activity (adjusted OR 0.34 [95% CI 0.18-0.66]; p=0.001) and with a better tolerability pattern. MET had six times more risk of discontinuation at 2 years (HR 5.97 [95% CI 2.92-12.20]). Index treatment was not associated with enrollment in tertiary education. Conclusion: HET as first-line strategy in POMS reduces the occurrence of a first-relapse with an optimal effect within the two first-years compared to treatment escalation, supporting a need to use immediate HET in POMS.

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 10/10/2023
• Auteurs : Perrine VerdysJavier Rey BarrosoJoseph VermeilThibaut SanchezArnaud MétaisThomas MangeatE. BellardClaire BigotJean-Philippe GirardIsabelle Maridonneau-PariniChristel VérolletFrédéric LagarrigueAlba Diz-MuñozJulien HeuvinghMatthieu PielOlivia Du RoureVéronique Le CabecSébastien CarrénoRenaud Poincloux
• Organismes : Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale Centre de Biologie Intégrative Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale Institut de pharmacologie et de biologie structurale European Molecular Biology Laboratory [Heidelberg] Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris Institut Pierre-Gilles de Gennes pour la Microfluidique Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris Institut de pharmacologie et de biologie structurale Institut de Recherche en Immunologie et en Cancérologie [UdeM-Montréal] Institut de pharmacologie et de biologie structurale

---

Résumé : The cellular actin cortex provides crucial mechanical support and plays critical roles in numerous functions, including cell division and migration. The proteins of the ERM family, ezrin, radixin, and moesin, are central to these processes by linking the plasma membrane to the actin cytoskeleton. To investigate the individual contributions of these three proteins to leukocyte migration, we generated single and triple ERM knockout macrophages. Surprisingly, we found that even in the absence of ERMs, macrophages can still form the different actin structures promoting cell migration, such as filopodia, lamellipodia, podosomes, and ruffles. Furthermore we discovered that, unlike every other cell type previously investigated, the single or triple knockout of ERMs does not affect macrophage migration in a large diversity of contexts. Finally, we demonstrated that the loss of ERMs in macrophages does not affect the mechanics of their actin cortex. These findings challenge the notion that .

---

Fichiers liés : P. Verdys et al. Biorxiv 2023.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/10/2023
• Auteurs : Mustapha MeftahCannelle ClavierAlain SarkissianAlain HauchecorneSlimane BekkiFranck LefèvrePatrick H. M. GalopeauPierre-Richard DahooAndrea PazmiñoAndré-Jean VieauChristophe DufourPierre MasoNicolas CaignardFrédéric FerreiraPierre GilbertOdile Hembise Fanton D’andonSandrine MathieuAntoine ManginCatherine BillardPhilippe Keckhut
• Organismes : STRATO - LATMOS Analytic and Computational Research, Inc. - Earth Sciences Laboratoire Atmosphères, Milieux, Observations Spatiales STRATO - LATMOS STRATO - LATMOS STRATO - LATMOS STRATO - LATMOS Laboratoire Atmosphères, Milieux, Observations Spatiales STRATO - LATMOS STRATO - LATMOS Laboratoire Atmosphères, Milieux, Observations Spatiales Laboratoire Atmosphères, Milieux, Observations Spatiales Laboratoire Atmosphères, Milieux, Observations Spatiales Laboratoire Atmosphères, Milieux, Observations Spatiales Laboratoire Atmosphères, Milieux, Observations Spatiales Laboratoire Atmosphères, Milieux, Observations Spatiales Analytic and Computational Research, Inc. - Earth Sciences Analytic and Computational Research, Inc. - Earth Sciences Analytic and Computational Research, Inc. - Earth Sciences Laboratoire Atmosphères, Milieux, Observations Spatiales STRATO - LATMOS
• Publié dans Remote Sensing le 28/10/2020

---

Résumé : Climate change is undeniably one of the most pressing and critical challenges facing humanity in the 21st century. In this context, monitoring the Earth’s Energy Imbalance (EEI) is fundamental in conjunction with greenhouse gases (GHGs) in order to comprehensively understand and address climate change. The French Uvsq-Sat NG pathfinder mission addresses this issue through the implementation of a Six-Unit CubeSat, which has dimensions of 111.3 × 36.6 × 38.8 cm in its unstowed configuration. Uvsq-Sat NG is a satellite mission spearheaded by the Laboratoire Atmosphères, Observations Spatiales (LATMOS), and supported by the International Satellite Program in Research and Education (INSPIRE). The launch of this mission is planned for 2025. One of the Uvsq-Sat NG objectives is to ensure the smooth continuity of the Earth Radiation Budget (ERB) initiated via the Uvsq-Sat and Inspire-Sat satellites. Uvsq-Sat NG seeks to achieve broadband ERB measurements using state-of-the-art yet straightforward technologies. Another goal of the Uvsq-Sat NG mission is to conduct precise and comprehensive monitoring of atmospheric gas concentrations (CO2 and CH4) on a global scale and to investigate its correlation with Earth’s Outgoing Longwave Radiation (OLR). Uvsq-Sat NG carries several payloads, including Earth Radiative Sensors (ERSs) for monitoring incoming solar radiation and outgoing terrestrial radiation. A Near-Infrared (NIR) Spectrometer is onboard to assess GHGs’ atmospheric concentrations through observations in the wavelength range of 1200 to 2000 nm. Uvsq-Sat NG also includes a high-definition camera (NanoCam) designed to capture images of the Earth in the visible range. The NanoCam will facilitate data post-processing acquired via the spectrometer by ensuring accurate geolocation of the observed scenes. It will also offer the capability of observing the Earth’s limb, thus providing the opportunity to roughly estimate the vertical temperature profile of the atmosphere. We present here the scientific objectives of the Uvsq-Sat NG mission, along with a comprehensive overview of the CubeSat platform’s concepts and payload properties as well as the mission’s current status. Furthermore, we also describe a method for the retrieval of atmospheric gas columns (CO2, CH4, O2, H2O) from the Uvsq-Sat NG NIR Spectrometer data. The retrieval is based on spectra simulated for a range of environmental conditions (surface pressure, surface reflectance, vertical temperature profile, mixing ratios of primary gases, water vapor, other trace gases, cloud and aerosol optical depth distributions) as well as spectrometer characteristics (Signal-to-Noise Ratio (SNR) and spectral resolution from 1 to 6 nm).

---

Fichiers liés : remotesensing-15-04876-v2.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 07/10/2023
• Auteurs : Yves Tranquille-MarquesJean-Philippe AiriauPierre BaudonIrwin IssuryAlain Mugnier
• Organismes : Centre d'études scientifiques et techniques d'Aquitaine (CESTA-CEA) Centre d'études scientifiques et techniques d'Aquitaine (CESTA-CEA) Centre d'études scientifiques et techniques d'Aquitaine (CESTA-CEA) Centre d'études scientifiques et techniques d'Aquitaine (CESTA-CEA) Centre d'études scientifiques et techniques d'Aquitaine (CESTA-CEA)

---

Résumé : The LMJ*, a 176-beam laser facility developed by the French Nuclear Science directorate CEA, is located at the CEA** CESTA site near Bordeaux. The LMJ facility is part of the French Simulation Program. It is designed to deliver about 1.4 MJ of energy on targets, for high energy density physics experiments, including fusion experiments. Since 2022, the LMJ facility aims at carrying out experiments with 12 bundles of 8 laser beams and 12 target diagnostics. In order to achieve daily shots including all the preparatory steps, the LMJ performs night activities from now on and the presence of technical operators is not required. These sequences work on vacuum windows inspection and beam alignment. They take into account all the prerequisites for their good performances and are scheduled automatically one after the other. They deal with material security and unexpected equipment alarms. They endeavour to required tasks success and give a detailed report of the night events to the shot director. This paper gives a presentation of the two sequences with solutions in order to answer the technical specifications and the last enhancements.

---

Source